Clinical Research Directory

Inclusion Criteria: * • Liver cirrhosis (clinical/radiological/histological diagnosis) * Indication for LOLA use (covert or over hepatic encephalopathy, Grad 0-2)) * Written informed consent * Age 18 -100 years Exclusion Criteria: * • Allergy to LOLA or its constituents, or to medications with a similar chemical structure (oral nutritional supplements are allowed when stable \>/= 8 weeks before and during the study) * Recent (\</= 8 weeks) changes of the dose of the lactulose therapy for hepatic encephalopathy * Rifaximin or any other antibiotic therapy within the past 4 weeks * Intake of LOLA in the past four weeks before inclusion * Intake of L-dopamine * Renal insufficiency with a serum creatinine \>3mg/dl * Hepatocellular carcinoma BCLC D under best supportive care * Inability to give informed consent * Pregnancy or breastfeeding * Participation in another interventional trial within the last 30 days